Home / Stocks / GMAB

Genmab A/S (GMAB, Biotechnology) Stock Valuation & Fair Value Fairly valued

Genmab A/S (GMAB, Biotechnology) trades at a blended P/E of 27.4, about 43% below its historical normal valuation, with a forward growth estimate of 37.2% and a PEG of 0.73. Analysts' one-year estimates have been hit 9% of the time.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-09-21
Blended P/E
27.4
Normal P/E
47.8
PEG
0.73
Fwd growth
37.2%
Div yield
0.0%
RSI (14)
64.9
Neutral
Technical context
  • Price $34.75 at the 2026-09-23 close, 2.9% above the 20-day average ($33.77) and 9.8% above the 50-day ($31.64).
  • RSI (14) at 64.9.
  • 52-week range $23.85 to $35.34: the price is 1.7% below the high and 45.7% above the low.

The Street vs SeerForecast

Wall Street's mean price target for GMAB is $39.14 across 11 analysts, 12.6% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 27.4 to 27.4 between 2026-09-19 and 2026-09-21, against a normal P/E of 47.8, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 27.4, Fairly valued (recalculated)2026-09-21: P/E 27.4, Fairly valued30.040.0Sep 19Sep 20Sep 21Normal P/E 47.8
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 27.4-43%Fairly valued
2026-09-21P/E 27.4-43%Fairly valued ← now

Frequently asked questions

Is Genmab A/S stock overvalued?

At a blended P/E of 27.4 versus its historical normal P/E of 47.8, Genmab A/S trades about 43% below its typical valuation, with a PEG of 0.73 on 37.2% forward growth. tickerseer currently rates it fairly valued.

What is Genmab A/S's fair value and PEG?

Genmab A/S trades at a blended P/E of 27.4 against a historical normal P/E of 47.8, a PEG of 0.73, and a forward growth estimate of 37.2%.

Has tickerseer's rating of Genmab A/S changed?

tickerseer's rating has been fairly valued since 2026-09-19.

What is the analyst price target for Genmab A/S?

The mean Wall Street price target for Genmab A/S is $39.14 across 11 analysts, 12.6% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track GMAB free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.